Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509
Qyuns Therapeutics Co., Ltd. Class H — H1 2025 Earnings Presentation
31 slides from Qyuns Therapeutics Co., Ltd. Class H's earnings presentation, Aug 19, 2025
Slide 1: Interim Results 2025
INTERIM RESULTS 2025 19 August 2025 2509.HK 0
Slide 2: Disclaimer
Disclaimer NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS By attending this presentation or by reading this document, you (1) agree to be bound by the
Slide 3: Qyuns at a Glance - Powering The Boom of China's Autoimmune Sector
Qyuns at a Glance - Powering The Boom of China's Autoimmune Sector with Comprehensive Capabilities A clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases Exclusive Focus Full Coverage Huge Market Comprehensive Pipeline Focus on autoimmune and
Slide 4: Exclusive Focus on Autoimmune and Allergic Disease Therapies, Covering Four Major Disease Areas
Exclusive Focus on Autoimmune and Allergic Disease Therapies, Covering Four Major Disease Areas And Key Therapeutic Pathways mAbs bring commercial certainty; bsAbs boost efficacy and patient compliance IL-12/IL-23p40 Psoriasis IL-23p19 Psoriasis Ankylosing Spondylitis IL-17A Atopic Dermatitis IL-4Rα
Slide 5: Seasoned Management Team with Extensive Industry Experience
Seasoned Management Team with Extensive Industry Experience And Successful Entrepreneurial Track Records Jianwei Li, Ph.D. Jiwan Qiu Deputy General Manager Executive Director, Chairman, General Manager Yiliang Wu Executive Director, 30 years of extensive R&D experience in biotechnology industry Gene
Slide 6: Overview
01 Innovative R&D Capability : Dual Engines Linking Past And Forging Future 02 Strategic Partnership Capability: Future Commercialization Guarantee Overview 03 Self-Sustaining Operations: Stronger Financial Performance Insurance 04 Financial Results 5
Slide 7: Innovative R&D Capability: Dual Engines Linking Past And Forging Future
Innovative R&D Capability : 01 Dual Engines Linking Past And Forging Future 6
Slide 8: 2025H1 Highlights
2025H1 Highlights 2025H1 sales performance of SAILEXIN is encouraging • On Oct 29, 2024, SAILEXIN, China’s first ustekinumab biosimilar, was approved with rapid nationwide sales launch; • As of June 30, 2025, Qyuns has shipped over 60,000 units to Zhongmei Huadong. Early stage bsAbs gradually form a
Slide 9: Comprehensive and Synergized Pipeline
Comprehensive and Synergized Pipeline BLA Drug Target Indication Preclinical IND Approval Phase I Phase II Phase III Partners Approval Ps QX001S IL-12/ SAILEXIN IL-23p40 CD PN AD CRSwNP QX005N IL-4Rα CSU Asthma COPD QX002N IL-17A AS Ps QX004N IL-23p19 CD Asthma QX008N TSLP COPD QX013N c-kit CSU QX02
Slide 10: Bridging Past & Future: MAbs for Strong Delivery; BsAbs for Innovative Portfolio
Bridging Past & Future: MAbs for Strong Delivery; BsAbs for Innovative Portfolio Pre-clinical IND Phase I Phase II Phase III BLA Marketed QX027N QX005N QX008N QX005N QX002N SAILEXIN SAILEXIN Dermatology Asthma Asthma CRSwNP AS CD +Respiratory Ps in adult QX030N QX005N QX004N QX008N QX005N CSU CD COP
Slide 11: Expected Progress of Certain Products in The Next Three Years
Expected Progress of Certain Products in The Next Three Years QX002N QX005N-PN BLA Submission BLA Submission QX030N QX005N-AD Phase III: Primary CTN Submission endpoint data (Australia) readout QX031N QX030N IND Submission Phase I: FPI (China and the U.S.) QX005N-PN QX031N QX005N-AD QX002N Phase III
Slide 12: SAILEXIN – 1st Ustekinumab Biosimilar Approved in China & Expected Blockbuster
SAILEXIN – 1st Ustekinumab Biosimilar Approved in China & Expected Blockbuster Market Opportunities and Competition Competitive Advantages Market Opportunities Ustekinumab Global Sales The first marketed Ustekinumab Biosimilar in China (SAILEXIN) ✓ The commercial collaboration with Huadong Medicine
Slide 13: QX005N – One of the Only Two IL-4Rα mAbs with BTD in China
QX005N – One of the Only Two IL-4Rα mAbs with BTD in China QX005N Strategic Cooperation • IL-4Rα controls the signaling of both IL-4 and IL-13, which is critical in the initiation of type 2 inflammation • QX005N is designed to inhibit IL-4Rα, a well-validated, ⚫ In July 2024, the exclusive joint dev
Slide 14: QX005N – 1st Biologic Drug Candidate for PN Developed by Chinese Domestic Company
QX005N – 1st Biologic Drug Candidate for PN Developed by Chinese Domestic Company Market Opportunities and Competition Unmet Medical Needs • Development of the PN drug market in China is still at an Limitation of Prevalence of PN in China, 2017-2030E current early stage Thousand treatment • Current
Slide 15: QX005N – Treatment for Moderate-to-Severe AD
QX005N – Treatment for Moderate-to-Severe AD Market Opportunities and Competition Unmet Medical Needs Market Opportunities • Systemic immunosuppressants face significant safety concerns AD patients in China reached 70.3 million in 2022 and is anticipated to reach 78.5 million in 2030, 30% of which a
Slide 16: QX002N – IL-17A mAb for AS
QX002N – IL-17A mAb for AS Market Opportunities and Competition Competitive Advantages Market Opportunities IL-17A vs. TNF The AS patient population in China reached 3.9 million in 2022, mainly younger ✓ Guided as 2L standalone treatment for AS, IL-17A inhibitors have shown adults clear clinical ben
Slide 17: QX004N – IL-23p19 mAb for Psoriasis and Crohn’s Disease
QX004N – IL-23p19 mAb for Psoriasis and Crohn’s Disease IL-23p19 is currently a better target for psoriasis Same target competitor The treatment effect of psoriasis will be further improved, The global sales of Skyrizi®, the same target competitor, were $1.59 and it is conducive to long-term managem
Slide 18: QX008N – TSLP mAb for Respiratory Diseases
QX008N – TSLP mAb for Respiratory Diseases Same target competitor •TSLP is a cytokine expressed by the airway epithelium and sits The global sales of Tezspire®, a competitor with the same target, were $174 at the top of multiple inflammatory cascades million in 2022 and $653 million in 2023, with an
Slide 19: QX013N – First Biologic Drug Candidate Targeting c-kit in China
QX013N – First Biologic Drug Candidate Targeting c-kit in China QX013N is a humanized IgG1 mAb independently developed by Qyuns and is the first biologic drug candidate targeting c-kit in China. Used for the treatment of chronic spontaneous urticaria (CSU). Mast cells are a key driver of the inflamm
Slide 20: Innovative BsAbs Portfolio: QX027N, QX031N, QX030N, QX035N
Innovative BsAbs Portfolio: Delivering Superior Solutions for Chronic Disease Management and Marking a New Era of Company Pipeline QX027N QX031N • Focusing on respiratory and skin diseases • Focusing on respiratory diseases • Planned IND filings in China and US in Q3 2025 • Planned IND filings in Ch
Slide 21: Strategic Partnership Capability: Future Commercialization Guarantee
Strategic Partnership Capability: 02 Future Commercialization Guarantee 20
Slide 22: R&D-Production-Commercialization Integrated Strategic Alliance
R&D-Production-Commercialization Integrated Strategic Alliance Early Research Pre-clinical Study Clinical Development Production Commercialization Innovative structural platform for rabbit 10 self-developed Process development & mAbs & BsAbs development product pipelines pilot platform Integrated an
Slide 23: Strategic Cooperation: Verify Pipeline Value, Generate Cash Income
Strategic Cooperation: Verify Pipeline Value, Generate Cash Income, Accelerate Clinical Progress, Enhance Commercial Certainty QX001S: strategic cooperation in Aug 2020 QX005N: strategic cooperation in Jul 2024 QX004N: strategic cooperation in Apr 2024 QX008N: strategic cooperation in Jan 2024 QX030
Slide 24: Self-Sustaining Operations: Stronger Financial Performance Insurance
Self-Sustaining Operations: 03 Stronger Financial Performance Insurance 23
Slide 25: Cellularforce: Commercial Scale Production Capacity Supporting CDMO Business Transformation
Cellularforce: Commercial Scale Production Capacity Supporting CDMO Business Transformation cGMP-standard manufacturing facility with excelled CMC capability One of only a few Chinese biotech companies that are focused on and quality management will secure high quality, cost controllable autoimmune
Slide 26: Strong Operational Cash-generating Capability Delivering Sustained Capital Reserves
Strong Operational Cash-generating Capability Delivering Sustained Capital Reserves Income from BD Income from CDMO & R&D services RMB 180M + RMB 22M + 25
Slide 27: Financial Results
0) =. © Financial Results
Slide 28: Significant Operating Income Increase further Strengthened Capital Reserves
Significant Operating Income Increase further Strengthened Capital Reserves Mil RMB 250 In 2025 H1, Qyuns recorded a total revenue of RMB 206.49 206.49 million, representing 359.7% increase 200 period-to-period. 150 In 2025 H1, company’s revenue mainly derived from upfront and milestone payments fro
Slide 29: Effective Expense Management Improves Operational Efficiency
Effective Expense Management Improves Operational Efficiency Mil RMB R&D Expenses of 2024 H1 – 2025 H1 Mil RMB Administrative Expenses of 2024 H1 – 2025 H1 160 151.39 80 70.33 150 145.23 70 60 140 48.27 50 130 40 30 120 20 110 10 100 0 2025.6.30 2024.6.30 2025.6.30 2024.6.30 In 2025 H1, Qyuns R&D ex
Slide 30: Cash Reserves Remain Stable with Optimized Loan Structure
Cash Reserves Remain Stable with Optimized Loan Structure Stable cash reserves: As of June 30, 2025, Cash and cash equivalents, time Cash and cash equivalents, time deposits, and deposits, and financial assets at fair value through profit or loss amounted to RMB financial assets at fair value throug
Slide 31: IR@qyuns.net
IR@qyuns.net 30